Evidence map›Paper›PMID 28404907›Full record

ArticleOncotarget2017

Investigation of three potential autoantibodies in Sjogren's syndrome and associated MALT lymphoma.

Li Cui, Naseim Elzakra, Shuaimei Xu, Gary Guishan Xiao, Yan Yang, Shen Hu

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 3 pooled it
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 3 syntheses or guidelines pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Cofilin(s) and Mitochondria: Function Beyond Actin Dynamics.International journal of molecular sciences · 2025
    Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. The Involvement of Alarmins in the Pathogenesis of Sjögren's Syndrome.International journal of molecular sciences · 2022
    Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 2 countries.

Li CuiUCLA School of Dentistry, Los Angeles, CA 90095, USA.
Naseim ElzakraUCLA School of Dentistry, Los Angeles, CA 90095, USA.
Shuaimei XuGuangdong Provincial Stomatological Hospital, Guangzhou 510000, China.
Gary Guishan XiaoSchool of Pharmaceutical Science and Technology, Dalian University of Technology, Dalian, 116024 China.
Yan YangUCLA School of Dentistry, Los Angeles, CA 90095, USA.
Shen HuUCLA School of Dentistry, Los Angeles, CA 90095, USA.
UCLA Health · USDalian University of Technology · CNGuangdong Province Stomatological Hospital · CNUniversity of California, Los Angeles · USWuhan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary Sjögren's syndrome (pSS) is a chronic autoimmune disease which might progress to mucosal-associated lymphoid tissue lymphoma (pSS/MALT). Diagnosis of pSS requires an invasive tissue biopsy and a delay in diagnosis of pSS has been frequently reported. In this study, four proteins including cofilin-1, alpha-enolase, annexin A2 and Rho GDP-dissociation inhibitor 2 (RGI2) were found to be over-expressed in pSS and pSS/MALT by 2D gel electrophoresis/mass spectrometry, and the finding was verified by the microarray analysis and western blotting results. We then developed enzyme-linked immunosorbent assays for autoantibodies including anti-cofilin-1, anti-alpha-enolase and anti-RGI2 with good quantitative ability. The expression levels of salivary anti-cofilin-1, anti-alpha-enolase and anti-RGI2 were found to be the highest in pSS/MALT patients and lowest in healthy controls. The combination of these three antiantibodies yielded an "area under the curve" (AUC) value of 0.94 with an 86% sensitivity and 93% specificity in distinguishing patients with pSS from healthy controls, an AUC value of 0.99 with a 95% sensitivity and 94% specificity in distinguishing patients with pSS/MALT from healthy controls and an AUC value of 0.86 with a 75% sensitivity and 94% specificity in distinguishing pSS/MALT patients from pSS patients. Collectively, we have successfully identified a panel of potential autoantigens that are progressively up-regulated during the development of pSS and its progression to MALT lymphoma. The autoantibody biomarkers may be used to help diagnose pSS and predict its progression to MALT lymphoma.

Indexed as

AutoantibodiesAutoantigensBiomarkersCase-Control StudiesElectrophoresis, Gel, Two-DimensionalEnzyme-Linked Immunosorbent AssayFemaleHumansLymphoma, B-Cell, Marginal ZoneMaleMass SpectrometryPrognosisProteomicsReproducibility of ResultsROC CurveSalivaAutoantibodiesAutoantigensBiomarkersalpha-enolasecofilin-1mucosal-associated lymphoid tissue lymphomaprimary Sjögren’s syndromeRho GDP-dissociation inhibitor 2

Identifiers

PMID28404907
PMCPMC5444724
OpenAlexW2590898850

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.